---
title: "GYRE: Global R&D engine advances novel degraders and DACs, funded by strong China commercial revenues"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297655933.md"
description: "A diversified pipeline of targeted protein degraders and DACs addresses major unmet needs in oncology, immunology, and fibrosis. Commercial revenues from China support global R&D, with F351 and ETUARY™ anchoring the fibrosis franchise and multiple assets advancing toward key clinical milestones.Original document: Gyre Therapeutics, Inc. [GYRE] Slides Release — Sep. 1 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-09-01T12:53:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297655933.md)
  - [en](https://longbridge.com/en/news/297655933.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297655933.md)
generator: "portal-rs"
---

# GYRE: Global R&D engine advances novel degraders and DACs, funded by strong China commercial revenues

A diversified pipeline of targeted protein degraders and DACs addresses major unmet needs in oncology, immunology, and fibrosis. Commercial revenues from China support global R&D, with F351 and ETUARY™ anchoring the fibrosis franchise and multiple assets advancing toward key clinical milestones.

Original document: Gyre Therapeutics, Inc. \[GYRE\] Slides Release — Sep. 1 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [GYRE.US](https://longbridge.com/en/quote/GYRE.US.md)

## Related News & Research

- [Gyre Therapeutics outlines protein degrader pipeline, China commercial outlook in corporate presentation](https://longbridge.com/en/news/297654775.md)
- [Gyre Therapeutics forecasts FY26 ETUARY revenue at $100.5 million-$111 million](https://longbridge.com/en/news/297050802.md)
- [Orum to begin Phase I trial of ORM-1153 after FDA clearance](https://longbridge.com/en/news/298030380.md)
- [Gyre Therapeutics unveils capital-efficient global development strategy](https://longbridge.com/en/news/297075877.md)
- [Gyre Therapeutics management to join Cantor Global Healthcare Conference fireside chat](https://longbridge.com/en/news/297902445.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**